Dried Blood Spot Viral Load Measurement via Cell Fixation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for measuring viral load in dried blood spots overestimate viral load due to the detection of cell-associated HIV DNA and RNA, leading to costly misclassification of patients as treatment failures, especially in resource-limited settings where plasma samples are not readily available.

Innovation Solution

A method involving rehydration of dried blood samples with a buffer solution, followed by fixation and elution using a fixing reagent like methanol and an eluting reagent like phosphate-buffered saline (PBS), which preferentially elutes cell-free virus particles without disrupting cell-associated RNA and DNA, allowing for separation and measurement of cell-free nucleic acids using techniques such as PCR or ELISA.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If total nucleic acid extraction is performed on dried blood spots using chaotropic agents, then complete extraction of HIV viral RNA and cell-associated DNA is achieved, but viral load is overestimated due to detection of cell-associated HIV DNA and RNA

Engineering Contradiction:
Improveextraction completenessVSAvoidviral load accuracy
Core Design Contradiction:
Quantity of substanceVSMeasurement precision

Solution Approach 1:

The patent segments the extraction process into two distinct phases: (1) cell lysis phase using chaotropic agents to release nucleic acids from cells, and (2) selective removal phase using DNase and RNase enzymes to degrade cell-associated DNA and RNA. This segmentation allows complete extraction of viral nucleic acids while eliminating contamination from cell-associated nucleic acids, thereby resolving the contradiction between extraction completeness and measurement accuracy

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces enzymatic intermediaries (DNase and RNase) as mediators that selectively degrade cell-associated DNA and RNA without affecting cell-free viral nucleic acids. These enzymes act as intermediate agents that bridge the gap between complete extraction and accurate measurement by selectively removing interfering substances while preserving the target analyte

Inventive Principle:
Principle #24Intermediary (Mediator)

2Ease of operation

If dried blood spots are used for viral load testing in resource-limited settings, then sample collection and storage is simplified, but measurement accuracy is compromised due to over-quantification

Engineering Contradiction:
Improvesample collection convenienceVSAvoidviral load accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent applies segmentation by dividing the complex extraction process into manageable sequential steps that can be performed with simple equipment: (1) cell lysis with chaotropic agent, (2) enzymatic treatment with DNase/RNase, and (3) nucleic acid purification. This segmented approach maintains the ease of DBS handling while achieving accurate viral load measurement through systematic removal of interfering substances

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent changes the chemical parameters of the extraction process by introducing enzymatic reactions (DNase and RNase treatment) that selectively modify cell-associated nucleic acids. This parameter change allows the method to maintain the simplicity of DBS processing while achieving plasma-equivalent accuracy by altering the nucleic acid composition during extraction

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly reduces over-quantification of viral load, achieving concordance with plasma viral load measurements and preventing misclassification of patients, thereby improving treatment decision-making with higher accuracy and reduced costs.

Implementation Method 1

fixing cells present in the rehydrated dried blood sample with a fixing reagent to contain cell-associated RNA and/or DNA with the cells

Methodology Applied
Scientific EffectProtein precipitation: Precipitation

Implementation Method 2

eluting cell-free nucleic acids and/or virus particles from the rehydrated dried blood sample with an eluting reagent that preferentially elutes cell-free virus particles

Methodology Applied
Scientific EffectElution: Solvation

Implementation Method 3

separating the cell-free nucleic acids and/or virus particles from any cell debris that may be present in the rehydrated dried blood sample by way of a filter

Methodology Applied
Scientific EffectFiltration: Filter (physical)

Data Source

PatentEP3060920B1Methods for measuring cell-free virus particles from dried blood spots
Publication Date: 2018.11.14 ROCHE DIAGNOSTICS GMBH
  • EP3060920B1 patent drawingFigure 1
  • EP3060920B1 patent drawingFigure 2
  • EP3060920B1 patent drawingFigure 3

AI summary

Methods for the measuring cell-free nucleic acids and/or virus particles from dried blood spots are described. The methods can include the steps of rehydrating a dried blood sample, optionally fixing cells present in the rehydrated dried blood sample, eluting cell-free virus particles from the rehydrated dried blood sample, separating the cell-free viruses from any cell debris that may be present in the rehydrated dried blood sample by way of a filter, and measuring cell-free virus particles by a viral particle quantification technique.